Successful treatment with infliximab of a patient with refractory sarcoidosis;Succesvolle behandeling met infliximab van een patiënt met therapieresistente sarcoïdose

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 49, 2004, Pages 2446-2450

  Fouchier, S M ^a,b   Moller G M ^a   Van Santen Hoeufft, M ^a   Faber, C G ^a   Smeenk, F W J M ^b   Drent, M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FATIGUE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG FUNCTION; LUNG SARCOIDOSIS; MALE; SARCOIDOSIS; THERAPY RESISTANCE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; DRUG RESISTANCE; GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; MALE; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS, PULMONARY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10244232877     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Drent M, Wirnsberger RM, Vries J de, Dieijen-Visser MP van, Wouters EFM, Schols AMWJ. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999;13:718-22.
2. Sharma OP. Fatigue and sarcoidosis. Eur Respir J 1999;13:713-4.
3. Hoitsma E, Marziniak M, Faber CG, Reulen JPH, Sommer C, Baets M de, et al. Small fibre neuropathy in sarcoidosis. Lancet 2002;359:2085-6.
4. Hunninghake GW, Costabel U, Ando M, Baughman RP, Cordier JF, du Bois RM, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149-73.
5. Gras M, Kemenade FJ van, Maarsseveen ACMTh van, Alberts C. Sarcoïdose: immunopathogenese en aanknopingspunten voor immunotherapie. Ned Tijdschr Geneeskd 2003;147:150-5.
6. Gordon N. Glycogenosis type V or McArdle's disease. Dev Med Child Neurol 2003;45:640-4.
7. Drent M, Vries J de, Lenters M, Lamers RJS, Rothkranz-Kos S, Wouters EFM, et al. Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 2003;13:2462-71.
8. Rothkrantz-Kos S, Dieijen-Visser MP van, Mulder PGH, Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003;49:1510-7.
9. Vries J de, Michielsen HJ, Heck GL van, Drent M. Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS). Br J Health Psychol 2004;9:279-91.
10. DeRemee RA. The roentgenographic staging of sarcoidosis. Historic and contemporary perspectives. Chest 1983;83:128-33.
11. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-8.
12. Fehrenbach H, Zissel G, Goldmann T, Tschernig T, Vollmer E, Pabst R, et al. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J 2003;21:421-8.
13. Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991;338:707-12.
14. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002;287:1301-7.
15. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002;121:24-31.
16. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 2002;122:227-32.
17. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vase Diffuse Lung Dis 2001;18:70-4.
18. Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 2003;48:3542-3.
19. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003;124:2028-31.
20. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 2004;150:146-9.
21. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
22. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Hogezand RA van, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
23. Vonkeman HE, Valk PDLPM van der, Mulder L, Laar MAFJ van de. Fatale miliaire tuberculose tijdens behandeling met infliximab. Ned Tijdschr Geneeskd 2002;140:1196-9.
24. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001;135:27-31.
25. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999;13 Suppl 4:16-22.